AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
"We've achieved what we set out to achieve," says Cobra's executive chairman Peter Fothergill, having announced a return to profitability after a tough two years. The biopharmaceutical manufacturer had a turbulent time after the bottom fell out of the plasmid DNA market and biotech customers in Europe struggled to attract investment. But refocusing on protein-based biopharmaceuticals and the US market has paid off handsomely. North American revenues rose 41 per cent in the year to GBP8.7m, while turnover from protein products roughly ...